Lu Jin-song, Li He-cheng, Cao Dao-cheng, Di Gen-hong, Wu Jiong, Shen Kun-wei, Shen Zhen-zou, Shao Zhi-min
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai 200032, China.
Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1318-21.
To study the effects of aromatase on breast cancer proliferation and invasive ability, so as to detect the relationship between in situ estrogen levels and molecular biological characteristics of breast cancer.
By immunohistochemistry staining, the expression of aromatase, matrix metalloproteinases 2 (MMP2) and matrix metalloproteinases (MMP 9) in the primary breast cancers were detected, the associations between aromatase and MMPs as well as clinical-pathological factors were analyzed.
The positive rates of aromatase were 25.0% (+) and 29.9% (++). Aromatase status was associated with MMP2, MMP9 and co-expression of MMP2 and MMP9 (P < 0.05), but not associated with tumor size, ER/PR status, menopausal status and tumor grade (P > 0.05). In the postmenopausal patients there was a relationship between aromatase and tumor size (P < 0.05), but not in the premenopausal patients (P > 0.05); there was a relationship between aromatase and co-expression of MMP2/MMP9 in the patients with ER and/or PR positive (P < 0.05), but not in the patients with ER and PR negative (P > 0.05).
In the breast cancer in situ estrogen produced by tumor aromatase may promote the cancer cells proliferation and invasiveness and maybe through ER pathway especially in the postmenopausal patients.
研究芳香化酶对乳腺癌增殖及侵袭能力的影响,以探寻原位雌激素水平与乳腺癌分子生物学特征之间的关系。
采用免疫组织化学染色法检测原发性乳腺癌中芳香化酶、基质金属蛋白酶2(MMP2)及基质金属蛋白酶9(MMP9)的表达,分析芳香化酶与基质金属蛋白酶以及临床病理因素之间的相关性。
芳香化酶阳性率为25.0%(+)和29.9%(++)。芳香化酶状态与MMP2、MMP9以及MMP2和MMP9的共表达相关(P<0.05),但与肿瘤大小、雌激素受体/孕激素受体(ER/PR)状态、绝经状态及肿瘤分级无关(P>0.05)。在绝经后患者中,芳香化酶与肿瘤大小相关(P<0.05),而在绝经前患者中则无相关性(P>0.05);在ER和/或PR阳性患者中,芳香化酶与MMP2/MMP9的共表达相关(P<0.05),而在ER和PR阴性患者中则无相关性(P>0.05)。
在乳腺癌中,肿瘤芳香化酶产生的原位雌激素可能促进癌细胞增殖及侵袭,可能通过ER途径,尤其是在绝经后患者中。